Ethical Criteria for Human Trials of Stem-Cell-Derived Dopaminergic Neurons in Parkinson's Disease

AJOB Neuroscience

Volumn 6, Issue 1, 2015, Pages 52-60

  Hurst, Samia A ^a   Mauron, Alex ^a   Momjian, Shahan ^b   Burkhard, Pierre R ^b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

ethics; Parkinson's disease; stem cells

Indexed keywords

EID: 84924284564     PISSN: 21507740     EISSN: 21507759     Source Type: Journal    
DOI: 10.1080/21507740.2014.990544     Document Type: Article

References (57)

1. Abdoler, E., H. Taylor, and D. Wendler. 2008. The ethics of phase 0 oncology trials. Clinical Cancer Research 14(12): 3692–3697. Available at: http://dx.doi.org/10.1158/1078-0432.CCR-08-0876
2. Agrawal, M., and E. J. Emanuel. 2003. Ethics of Phase 1 oncology studies: Reexamining the arguments and data. Journal of the American Medical Association 290(8): 1075–1082. Available at: http://dx.doi.org/10.1001/jama.290.8.1075
3. Albin, R. L. 2002. Sham surgery controls: Intracerebral grafting of fetal tissue for Parkinson's disease and proposed criteria for use of sham surgery controls. Journal of Medical Ethics 28(5): 322–325. Available at: http://dx.doi.org/10.1136/jme.28.5.322
4. Albin, R. L. 2005. Sham surgery controls are mitigated trolleys. Journal of Medical Ethics 31(3): 149–152. Available at: http://dx.doi.org/10.1136/jme.2003.006155
5. Alterman, R. L., M. Tagliati, and C. W. Olanow. 2011. Open-label surgical trials for Parkinson disease: Time for reconsideration. Annals of Neurology 70(1): 5–8. Available at: http://dx.doi.org/10.1002/ana.22453
6. Appelbaum, P. S., C. W. Lidz, and T. Grisso. 2004. Therapeutic misconception in clinical research: Frequency and risk factors. IRB 26(2): 1–8
7. Bretzner, F., F. Gilbert, F. Baylis, and R. M. Brownstone. 2011. Target populations for first-in-human embryonic stem cell research in spinal cord injury. Cell Stem Cell 8(5): 468–475. Available at: http://dx.doi.org/10.1016/j.stem.2011.04.012
8. Brundin, P., O. Pogarell, P. Hagell, et al. 2000. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 123(Pt 7): 1380–1390.
9. Buchanan, A. E., and D. W. Brock. 1990. Deciding for others: The ethics of surrogate decision making. Cambridge, UK: Cambridge University Press.
10. Buffo, A., I. Rite, P. Tripathi, et al. 2008. Origin and progeny of reactive gliosis: A source of multipotent cells in the injured brain. Proceedings of the National Academy of Sciences of the United States of America 105(9): 3581–3586. Available at: http://dx.doi.org/10.1073/pnas.0709002105
11. Cochen, V., M. J. Ribeiro, J. P. Nguyen, et al. 2003. Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue. Movement Disorders 18(8): 928–932. Available at: http://dx.doi.org/10.1002/mds.10463
12. Cohen, P. D., L. Herman, S. Jedlinski, P. Willocks, and P. Wittekind. 2007. Ethical issues in clinical neuroscience research: A patient's perspective. Neurotherapeutics 4(3): 537–544. Available at: http://dx.doi.org/10.1016/j.nurt.2007.04.008
13. Cohen, P. D., T. Isaacs, P. Willocks, et al. 2012. Sham neurosurgical procedures: The patients' perspective. Lancet Neurology 11(12): 1022. Available at: http://dx.doi.org/10.1016/S1474-4422(12)70277-6
14. Council for International Organizations of Medical Sciences. 2002. International ethical guidelines for biomedical research involving human subjects. Geneva, Switzerland: CIOMS.
15. DCCT Research Group. 1989. Implementation of a multicomponent process to obtain informed consent in the Diabetes Control and Complications Trial. Controlled Clinical Trials 10(1): 83–96. Available at: http://dx.doi.org/10.1016/0197-2456(89)90020-2
16. de Melo-Martin, I., and A. Ho. 2008. Beyond informed consent: The therapeutic misconception and trust. Journal of Medical Ethics 34(3): 202–205.
17. Dorsey, E. R., R. Constantinescu, J. P. Thompson, et al. 2007. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68(5): 384–386. Available at: http://dx.doi.org/10.1212/01.wnl.0000247740.47667.03
18. Emanuel, E. J., D. Wendler, and C. Grady. 2000. What makes clinical research ethical? Journal of the American Medical Association 283(20): 2701–2711. Available at: http://dx.doi.org/10.1001/jama.283.20.2701
19. Escher, M., and S. A. Hurst. 2011. The ethics of research on pain and other symptoms. In Clinical ethics in anesthesiology, ed. G. Van Norman, S. Palmer, S. Jackson, S. Rosenbaum, and A. Cahana, 1993–1998. New York, NY: Cambridge University Press.
20. Fawcett, J. W., and R. A. Asher. 1999. The glial scar and central nervous system repair. Brain Research Bulletin 49(6): 377–391. Available at: http://dx.doi.org/10.1016/S0361-9230(99)00072-6
21. Frank, S., K. Kieburtz, R. Holloway, and S. Y. Kim. 2005. What is the risk of sham surgery in Parkinson disease clinical trials? A review of published reports. Neurology 65(7): 1101–1103. Available at: http://dx.doi.org/10.1212/01.wnl.0000171957.90640.b5
22. Freed, C. R., M. A. Leehey, M. Zawada, et al. 2003. Do patients with Parkinson's disease benefit from embryonic dopamine cell transplantation? Journal of Neurology 250(Suppl 3): III44–46.
23. Freed, C. R., P. E. Greene, R. E. Breeze, et al. 2001. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. New England Journal of Medicine 344(10): 710–719. Available at: http://dx.doi.org/10.1056/NEJM200103083441002
24. Galpern, W. R., J. Corrigan-Curay, A. E. Lang, et al. 2012. Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: Scientific and ethical considerations. Lancet Neurology 11(7): 643–650. Available at: http://dx.doi.org/10.1016/S1474-4422(12)70064-9
25. Gilbert, D. T., and T. D. Wilson. 2009. Why the brain talks to itself: Sources of error in emotional prediction. Philosophical Transactions of the Royal Society B: Biological Sciences 364(1521): 1335–1341. Available at: http://dx.doi.org/10.1098/rstb.2008.0305
26. Goetz, C. G., J. Wuu, M. P. McDermott, et al. 2008. Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions. Movement Disorders 23(5): 690–699. Available at: http://dx.doi.org/10.1002/mds.21894
27. Hagell, P., and P. Brundin. 2001. Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. Journal of Neuropathology and Experimental Neurology 60(8): 741–52.
28. Hagell, P., A. Schrag, P. Piccini, et al. 1999. Sequential bilateral transplantation in Parkinson's disease: Effects of the second graft. Brain 122(part 6): 1121–1132.
29. Hauser, R. A., R. L. Watts, T. B. Freeman et al. 2001. A double-blind randomized, controlled, multicenter clinical trial of the safety and efficacy of transplanted fetal porcine ventral mesencephalic cells vs. imitation surgery in patients with Parkinson's disease. Movement Disorders 16: 983–984.
30. Hauser, R. A., T. B. Freeman, B. J. Snow, et al. 1999. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Archives of Neurology 56(2): 179–187. Available at: http://dx.doi.org/10.1001/archneur.56.2.179
31. Henderson, G. E., L. R. Churchill, A. M. Davis, et al. 2007. Clinical trials and medical care: Defining the therapeutic misconception. PLoS Medicine 4(11): e324. Available at: http://dx.doi.org/10.1371/journal.pmed.0040324
32. Horng, S., and F. G. Miller. 2002. Is placebo surgery unethical? New England Journal of Medicine 347(2): 137–139. Available at: http://dx.doi.org/10.1056/NEJMsb021025
33. Horng, S., and F. G. Miller. 2003. Ethical framework for the use of sham procedures in clinical trials. Critical Care Medicine 31(3 suppl.): S126–S130. Available at: http://dx.doi.org/10.1097/01.CCM.0000054906.49187.67
34. Ilic, N., A. Auchlin, A. Hadengue, A. Wenger, and S. A. Hurst. 2013. Informed consent forms in oncology research: Linguistic tools identify recurrent pitfalls. AJOB Empirical Bioethics 4(4): 39–54.
35. Kahneman, D., A. B. Krueger, D. Schkade, N. Schwarz, and A. A. Stone. 2006. Would you be happier if you were richer? A focusing illusion. Science 312(5782): 1908–1910. Available at: http://dx.doi.org/10.1126/science.1129688
36. Katsnelson, A. 2011. Experimental therapies for Parkinson's disease: Why fake it? Nature 476(7359): 142–144. Available at: http://dx.doi.org/10.1038/476142a
37. Kim, S. Y., S. Frank, R. Holloway, et al. 2005. Science and ethics of sham surgery: A survey of Parkinson disease clinical researchers. Archives of Neurology 62(9): 1357–1360. Available at: http://dx.doi.org/10.1001/archneur.62.9.1357
38. Kimmelman, J., A. J. London, B. Ravina, et al. 2009. Launching invasive, first-in-human trials against Parkinson's disease: Ethical considerations. Movement Disorders 24(13): 1893–1901. Available at: http://dx.doi.org/10.1002/mds.22712
39. Kordower, J. H., Y. Chu, R. A. Hauser, T. B. Freeman, and C. W. Olanow. 2008. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nature Medicine 14(5): 504–506. Available at: http://dx.doi.org/10.1038/nm1747
40. Li, J. Y., E. Englund, J. L. Holton, et al. 2008. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nature Medicine 14(5): 501–503. Available at: http://dx.doi.org/10.1038/nm1746
41. Lindvall, O., P. Brundin, H. Widner, et al. 1990. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 247(4942): 574–577
42. Lo, B., and L. Parham. 2010. Resolving ethical issues in stem cell clinical trials: The example of Parkinson disease. Journal of Law, Medicine & Ethics 38(2): 257–266. Available at: http://dx.doi.org/10.1111/j.1748-720X.2010.00486.x
43. Macklin, R. 1999. The ethical problems with sham surgery in clinical research. New England Journal of Medicine 341(13): 992–996. Available at: http://dx.doi.org/10.1056/NEJM199909233411312
44. Master, Z., M. McLeod, and I. Mendez. 2007. Benefits, risks and ethical considerations in translation of stem cell research to clinical applications in Parkinson's disease. Journal of Medical Ethics 33(3): 169–173. Available at: http://dx.doi.org/10.1136/jme.2005.013169
45. Mathews, D. J., J. Sugarman, H. Bok, et al. 2008. Cell-based interventions for neurologic conditions: Ethical challenges for early human trials. Neurology 71(4): 288–293. Available at: http://dx.doi.org/10.1212/01.wnl.0000316436.13659.80
46. Mendez, I., A. Dagher, M. Hong, et al. 2000. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. Journal of Neurosurgery 92(5): 863–869. Available at: http://dx.doi.org/10.3171/jns.2000.92.5.0863
47. Mendez, I., A. Vinuela, A. Astradsson, et al. 2008. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nature Medicine 14(5): 507–509. Available at: http://dx.doi.org/10.1038/nm1752
48. Olanow, C. W. 2014. Parkinson disease: Gene therapy for Parkinson disease—A hope, or a dream? Nature Reviews Neurology 10(4): 186–187. Available at: http://dx.doi.org/10.1038/nrneurol.2014.45
49. Olanow, C. W., C. G. Goetz, J. H. Kordower, et al. 2003. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Annals of Neurology 54(3): 403–414. Available at: http://dx.doi.org/10.1002/ana.10720
50. Regenberg, A., D. J. Mathews, D. M. Blass, et al. 2009. The role of animal models in evaluating reasonable safety and efficacy for human trials of cell-based interventions for neurologic conditions. Journal of Cerebral Blood Flow & Metabolism 29(1): 1–9. Available at: http://dx.doi.org/10.1038/jcbfm.2008.98
51. Russmann, H., J. Ghika, J. G. Villemure, et al. 2004. Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years. Neurology 63(10): 1952–1954. Available at: http://dx.doi.org/10.1212/01.WNL.0000144198.26309.D8
52. Solbakk, J. H. and L. Zoloth. 2011. The tragedy of translation: The case of “first use” in human embryonic stem cell research. Cell Stem Cell 8(5): 479–481. Available at: http://dx.doi.org/10.1016/j.stem.2011.04.009
53. Sudore, R. L., C. S. Landefeld, B. A. Williams, et al. 2006. Use of a modified informed consent process among vulnerable patients: A descriptive study. Journal of General Internal Medicine 21(8): 867–873. Available at: http://dx.doi.org/10.1111/j.1525-1497.2006.00535.x
54. Swift, T. L. 2012. Sham surgery trial controls: Perspectives of patients and their relatives. Journal of Empirical Research on Human Research Ethics 7(3): 15–28. Available at: http://dx.doi.org/10.1525/jer.2012.7.3.15
55. Vellas, B., N. Coley, and S. Andrieu. 2008. Disease modifying trials in Alzheimer's disease: Perspectives for the future. Journal of Alzheimer's Disease 15(2): 289–301.
56. Wendler, D., and C. Grady. 2008. What should research participants understand to understand they are participants in research? Bioethics 22(4): 203–208. Available at: http://dx.doi.org/10.1111/j.1467-8519.2008.00632.x
57. World Medical Association. 2008. Declaration of Helsinki: Ethical principles for medical research involving human subjects. Available at: Available at: http://www.wma.net/e/policy/b3.htm (accessed February24, 2009).